Cambrian Biopharma
| File:Cambrian Biopharma company logo.png | |
| ISIN | 🆔 |
|---|---|
| Industry | Venture capital, pharmaceuticals |
| Founded 📆 | 2019[1] |
| Founders 👔 | James Peyer[2] Christian Angermayer[3] |
| Headquarters 🏙️ | New York, NY[4] |
Area served 🗺️ | |
Key people | James Peyer (CEO)[2] Christian Angermayer (Chairman) |
| Products 📟 | Research, development and funding for anti-aging drugs |
| Members | |
Number of employees | |
| 🌐 Website | www |
| 📇 Address | |
| 📞 telephone | |
Cambrian Biopharma ("Cambrian") is a New York City-based biotechnology investment company that invests in anti-aging research. The company studies the biological basis of aging, such as cellular wear and tear or mutations in DNA, and funds related treatments to slow the processes.[2]
History[edit]
Cambrian was co-founded in 2019 by James Peyer, a PhD in stem cell biology and former co-founder and managing partner at health-focused venture capital firm Apollo Ventures, along with billionaire investor and entrepreneur Christian Angermayer.[5][1][3] The company identifies and invests in new discoveries from university or other labs that target different causes or potential causes of aging.[6] The successful drugs would then be funded and spun off as standalone companies.[6] Peyer became the company's CEO, and Angermayer became Chairman.[7]
In October 2020, Cambrian and venture capital firm H&S Ventures co-led a $29 million funding round for bacteriophage cancer therapy company Sensei Biotherapeutics.[8] It was Cambrian's first portfolio company.[9]
In February 2021, Sensei Biotherapeutics began publicly trading with an IPO and raised $133 million at a valuation of $600 million.[7] Later in February, Cambrian exited Stealth mode and announced it had raised $60 million in private financing to develop medicines to extend lifespans.[7] In June, Cambrian led a $32 million Series A funding round for stem cell engineering company Vita Therapeutics, a spin off from Johns Hopkins.[10] It was Cambrian's second portfolio company.[9] In October, Cambrian secured a $100 million Series C funding round, intended to fund three to five clinical trials in the following 18 months.[3] The round was co-led by investment firm Anthos Capital and SALT Fund, an investment arm of SkyBridge Capital, with participation from existing backers Apeiron Investment, Future Ventures and Moore Capital.[3] At the time, CEO Peyer announced that the company expected to have 18 drug candidates by the end of 2021.[4]
In February 2022, Cambrian announced it had licensed rights to mTOR inhibitor programs from Swiss pharmaceutical corporation Novartis.[11] As part of the deal, Cambrian was setting up a subsidiary called Tornado Therapeutics.[11]
Business model[edit]
Cambrian researches and develops treatments to slow the effects of aging, to extend the number of years an individual can enjoy a healthy life.[2] It has identified 14 new therapies that are under development to treat and prevent diseases of aging.[1] Due to the difficulty of running clinical trials for anti-aging drugs, Cambrian identifies drugs that are promising candidates for aging diseases, finds a safe application of the drug for a current disease, and then once it is approved, applies for use for elderly patients to prevent the aging disease.[1]
As of 2021, Cambrian was focusing on three categories of aging: intracellular dysfunction, cellular dysfunction and tissue level dysfunction.[7] Its research includes muscle stem cell treatments for a rare form of childhood muscular dystrophy cancer.[9]
Spinouts[edit]
The following companies were funded and launched by Cambrian:
Operations[edit]
Cambrian is headquartered in New York City.[4] James Peyer is the company's CEO, and Christian Angermayer is the company's Chairman.[7] Former Allergan R&D Chief Brent Saunders sits on the Cambrian board.[3]
References[edit]
- ↑ 1.0 1.1 1.2 1.3 "The Startup That May Hold the Key to Extending Human Life". Bloomberg. October 26, 2021. Retrieved March 14, 2022.
- ↑ 2.0 2.1 2.2 2.3 "Silicon Valley is chasing the fountain of youth". Axios. September 25, 2021. Retrieved March 14, 2022.
- ↑ 3.0 3.1 3.2 3.3 3.4 "Cambrian secures $100M series C for Roivant-like approach to biotech creation with goal to slow down human aging". Fierce Biotech. October 26, 2021. Retrieved March 14, 2022.
- ↑ 4.0 4.1 4.2 "SoHo biotech raises $100M Series C to target age-related diseases". Crain's New York Business. October 27, 2021. Retrieved March 14, 2022.(subscription required)
- ↑ "Cambrian is Using a New Drug Discovery Model to Solve the Science of Aging". PM360. April 26, 2011. Retrieved March 14, 2022.
- ↑ 6.0 6.1 "Brent Saunders joins $100M Series C for a company out to be the BridgeBio of aging". Endpoints News. October 26, 2021. Retrieved March 14, 2022.
- ↑ 7.0 7.1 7.2 7.3 7.4 7.5 "New York-based biotech raises $60 million to develop a pipeline of companies and therapeutics to treat diseases of aging under its unique operational strategy". Longevity Technology. February 9, 2021. Retrieved March 14, 2022.
- ↑ "Sensei raises $29M to advance anti-cancer bacteriophage pipeline". Fierce Biotech. October 9, 2020. Retrieved March 14, 2022.
- ↑ 9.0 9.1 9.2 "UPDATED: Can a cell therapy treat muscular dystrophy? A German billionaire's anti-aging startup is trying to find out". Endpoints News. June 24, 2021. Retrieved March 14, 2022.
- ↑ 10.0 10.1 "Cambrian spun off Baltimore stem cell startup Vita Therapeutics raises $32M". Baltimore Business Journal. June 23, 2021. Retrieved March 14, 2022.
- ↑ 11.0 11.1 11.2 "Novartis vet is getting another shot at mTOR following the implosion of a longevity pioneer". Endpoints. February 16, 2022. Retrieved March 14, 2022.
External links[edit]
This article "Cambrian Biopharma" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Cambrian Biopharma. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
